Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

In addition to wanting to see a Brilacidin phIII OM trial, I'd also like to see a Brilacidin phIII ABSSSI trial since both are ready for phIII.

My belief from the pr's and SEC filings is that the company is looking at Brilacidin phII for UC next.

If Brilacidin phII Covid trials are successful funds should come up for revisiting Kevetrin too.

In the meantime, we wait to hear outcome of Covid trials.

Thanks for your time.

Btw, I believe Dr Sonis does periodic consulting work for IPIX.







Message in reply to: Bolded

I believe that more than 90% have surgery before CRT.

https://pubmed.ncbi.nlm.nih.gov/32861702/

Quote:
Results: Among 1316 OSCC patients treated with curative-intent; 108 patients (8%) received non-operative management due to: medical inoperability (n = 14, 13%), surgical unresectability (n = 8, 7%), patient declined surgery (n = 15, 14%), attempted preservation of oral structure/function in view of required extensive surgery (n = 53, 49%) or extensive oropharyngeal involvement (n = 18, 17%).

Surgery is the main treatment modality for OSCC while postoperative radiation therapy (PORT) is indicated mainly for patients with advanced disease (e.g. pT3-4, pN2-3) or adverse pathologic/treatment features (e.g. close resection margin), and concurrent chemotherapy with PORT for patients with high risk features (positive microscopic resection margin[s] and/or pathologic extranodal extension) [1], [2], [3], [4], [5]


Almost everyone gets surgery if they can. The sooner the better.

Dr. Sonis didn't say anything about brilacidin other than the excerpt I posted. I don't know how he feels about it.

I think it's worth another trial if we have the money to risk. It is a big market, and there is a strong need for some drug to help.

Soligenix trial failed on top line for their phase 3 trial in December 2020. It looks like Sonis wrote the article in October 2020, so that's probably why he said no definitive results for a while. SGNX trial was the most advanced.

https://apnews.com/press-release/pr-newswire/business-technology-public-health-government-business-and-finance-health-care-policy-2a78c97ebf2e64fb5d3162a46b4e8cda

Will see if they go after secondary endpoints for approval or scrap the program.